# A Study of Various Respiratory Syncytial Virus (RSV) Pre-Fusion (preF)-Based Vaccine Formulations in Adults Aged 60 Years and Older

> **NCT05327816** · PHASE1,PHASE2 · TERMINATED · sponsor: **Janssen Vaccines & Prevention B.V.** · enrollment: 132 (actual)

## Conditions studied

- Respiratory Syncytial Virus-associated Lower Respiratory Tract Disease Prevention

## Interventions

- **BIOLOGICAL:** RSV preF-based Vaccine
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05327816
- **Lead sponsor:** Janssen Vaccines & Prevention B.V.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-04-13
- **Primary completion:** 2023-01-16
- **Final completion:** 2023-02-14
- **Target enrollment:** 132 (ACTUAL)
- **Why stopped:** Based on recent study data from VAC18193, it was decided to terminate the study. There are no underlying safety concerns to terminate VAC18195RSV1001
- **Last updated:** 2025-05-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05327816

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05327816, "A Study of Various Respiratory Syncytial Virus (RSV) Pre-Fusion (preF)-Based Vaccine Formulations in Adults Aged 60 Years and Older". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT05327816. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*